{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:50:07Z","timestamp":1789059007994,"version":"build-2803163510"},"reference-count":20,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Symmetrical drug\u2010related intertriginous and flexural exanthema (SDRIFE) is a rare, symmetrical skin eruption triggered by various medications, predominantly beta\u2010lactam antibiotics. We report the case of a 69\u2010year\u2010old male with moderate\u2010to\u2010severe ulcerative colitis who developed SDRIFE following the seventh intravenous administration of infliximab. The patient presented with symmetrical, pruritic erythema in the cubital and popliteal fossae, groins, gluteal and retroauricular regions without systemic involvement. Skin biopsy showed mild exocytosis of T lymphocytes in the epidermis and dense superficial perivascular CD3+ and CD4+ infiltration, consistent with a type IVa hypersensitivity reaction. The patient responded well to a regimen of systemic antihistamines, topical corticosteroids and tacrolimus ointment, with complete regression of lesions within one week. Despite mild recurrences of SDRIFE after each infliximab administration, the therapy was not discontinued due to the mild nature of the reaction and favourable prognosis. The authors are not aware of previously published cases of type IVa SDRIFE induced by infliximab. Unlike previous reports of severe type IVc SDRIFE reactions requiring discontinuation of infliximab, our case highlights the predominance of CD4+ cells, which may explain the mild clinical course. Understanding the underlying immunologic mechanisms of infliximab\u2010induced SDRIFE could affect treatment decisions and prevent unnecessary discontinuation of effective therapies.<\/jats:p>","DOI":"10.1111\/bcp.16390","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T05:09:57Z","timestamp":1736399397000},"page":"903-907","source":"Crossref","is-referenced-by-count":3,"title":["Infliximab\u2010induced symmetrical drug\u2010related intertriginous and flexural exanthema (SDRIFE) in a patient with ulcerative colitis"],"prefix":"10.1111","volume":"91","author":[{"given":"Mislav","family":"Mokos","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology Sestre Milosrdnice University Hospital Centre  Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedrana","family":"Bulat","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Sestre Milosrdnice University Hospital Centre  Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1413-4862","authenticated-orcid":false,"given":"Robert","family":"Liki\u0107","sequence":"additional","affiliation":[{"name":"University of Zagreb School of Medicine  Zagreb Croatia"},{"name":"Division for Clinical Pharmacology and Therapeutics Department of Internal Medicine University Hospital Centre Zagreb  Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Bosni\u0107","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Sestre Milosrdnice University Hospital Centre  Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slavko","family":"Ga\u0161parov","sequence":"additional","affiliation":[{"name":"University of Zagreb School of Medicine  Zagreb Croatia"},{"name":"Department of Pathology and Cytology Merkur University Hospital  Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105\u20101873.2004.00445.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.5070\/D36QK5R7NV"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.10.015"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13130"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.1836"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1039\/d1md00200g"},{"key":"e_1_2_7_8_1","first-page":"1","volume-title":"Rook's textbook of dermatology","author":"Ardern\u2010Jones MR","year":"2016"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.601954"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e3283489d5f"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.13084"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/2045\u20107022\u20105\u2010s1\u2010o1"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjw007"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u20100536.1983.tb04439.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u20100536.1984.tb00343.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2015.03.007"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000436951.80898.6d"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140538"},{"issue":"4","key":"e_1_2_7_19_1","first-page":"322","article-title":"Symmetrical drug\u2010related intertriginous and flexural exanthema (baboon syndrome) associated with infliximab: a case\u2010based review","volume":"1","author":"Keshavamurthy C","year":"2022","journal-title":"ARP Rheumatol"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.3315\/jdcr.2015.1190"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13882"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.16390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T08:17:44Z","timestamp":1741767464000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.16390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/bcp.16390"],"URL":"https:\/\/doi.org\/10.1111\/bcp.16390","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]}}}